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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a herpesvirus that is linked to Kaposi’s
sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman’s disease
(MCD). KSHV establishes persistent latent infection in the human host. KSHV undergoes
periods of spontaneous reactivation where it can enter the lytic replication phase of its life-
cycle. During KSHV reactivation, host innate immune responses are activated to restrict
viral replication. Here, we report that NLRX1, a negative regulator of the type I interferon
response, is important for optimal KSHV reactivation from latency. Depletion of NLRX1 in
either iSLK.219 or BCBL-1 cells significantly suppressed global viral transcription levels
compared to the control group. Concomitantly, fewer viral particles were present in either
cells or supernatant from NLRX1 depleted cells. Further analysis revealed that upon NLRX1
depletion, higher IFNβ transcription levels were observed, which was also associated with a
transcriptional upregulation of JAK/STAT pathway related genes in both cell lines. To inves-
tigate whether IFNβ contributes to NLRX1’s role in KSHV reactivation, we treated control
and NLRX1 depleted cells with a TBK1 inhibitor (BX795) or TBK1 siRNA to block IFNβ pro-
duction. Upon BX795 or TBK1 siRNA treatment, NLRX1 depletion exhibited less inhibitory
effects on reactivation and infectious virion production, suggesting that NLRX1 facilitates
KSHV lytic replication by negatively regulating IFNβ responses. Our data suggests that
NLRX1 plays a positive role in KSHV lytic replication by suppressing the IFNβ response dur-
ing the process of KSHV reactivation, which might serve as a potential target for restricting
KSHV replication and transmission.
Author summary
Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked to a number of different
human cancers, including Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD). KSHV predominantly establishes life-long
latency in the infected host. Lytic reactivation from latency is critical for KSHV survival
and replication. During KSHV reactivation from latency, host innate immune responses
are activated to restrict viral replication. Here, we report that NLRX1, a negative regulator
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of the type I interferon response, is important for optimal KSHV reactivation and subse-
quent lytic replication.
Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-
8), is a linear double-stranded DNA virus. It is causally linked with Kaposi’s sarcoma (KS), pri-
mary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) [1, 2]. In the
majority of KS lesion cells or PEL cells, KSHV maintains latent infection, where KSHV lytic
gene expression can only be detected in a small subset of cells [3]. While latent infection is
important for maintaining the viral reservoir, reactivation of KSHV from latent infection is
important for viral particle production and transmission of KSHV [4, 5]. The balance between
lytic and latent infection is critical for KSHV pathogenicity. During reactivation, many cellular
signaling pathways are activated and regulated by both host and viral proteins. For example,
KSHV infection has been shown to trigger innate immune responses through pattern recogni-
tion receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs), which
results in interferon and pro-inflammatory cytokine production (reviewed in [6]). KSHV
encodes multiple proteins that modulate host immune responses to facilitate viral replication
[7–11]. However, a better understanding of the role of cellular genes in viral reactivation is
also critical for understanding the pathogenesis associated with KSHV.
NLRX1 (also known as CLR11.3 and NOD9) is a member of nucleotide-binding domain,
leucine-rich repeat-containing protein family (also known as NOD-like receptors, NLRs) [12–
14]. NLRs were originally widely studied as sensors or receptors of inflammasome signaling,
but were recently reported to regulate type I interferon production as well (reviewed in [15,
16]). NLRX1 was identified as a negative regulator of RIG-I like receptor (RLR) dependent type
I interferon production [12]. NLRX1 localizes to the mitochondria and associates with MAVS
(also known as Cardif, VISA and IPS-1), a mitochondria-localized adaptor downstream of
RIG-I, to disrupt cytosolic RNA induced type I interferon responses. Depletion of NLRX1 led
to enhanced antiviral responses [12]. Notably, NLRX1 was also identified to facilitate HIV-1
primary infection through negative regulation of the cytosolic DNA sensing pathway. NLRX1
was shown to sequester the DNA-sensing adaptor STING from interaction with TBK-1, and
therefore block sufficient type I interferon production. In a similar vein, NLRX1 deficient mice
also exhibited stronger innate immune responses and thus reduced HSV1 replication [17]. In
correlation with these findings, in SIV infection of rhesus monkeys, expression of NLRX1 was
negatively correlated with a type I interferon signature [18]. Therefore, in the context of viral
infection, NLRX1 might be a key factor in determining the battle between host and virus.
KSHV reactivation has been previously reported to activate MAVS-dependent cytosolic
RNA sensing pathways. Blocking MAVS was shown to downregulate type I interferon and
thus facilitate KSHV lytic replication [19]. Therefore, as a MAVS negative regulator, it is plau-
sible that NLRX1 plays an important role in KSHV reactivation, and functions as a potential
target for restricting KSHV transmission.
Results
NLRX1 is required for optimal KSHV reactivation
To investigate the role of NLRX1 as a potential restriction factor against KSHV lytic reactiva-
tion from latency, we utilized KSHV latently infected epithelial cells, iSLK.219 cells [20]. We
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used control siRNA or siRNA against NLRX1 to specifically deplete NLRX1 in iSLK.219 cells
before reactivation. The iSLK.219 cells harbor a latent BAC16-KSHV with a constitutive GFP
marker, a doxycycline (Dox)-inducible RTA, which is necessary and sufficient to induce lytic
reactivation, and a RFP marker driven by the promoter of the KSHV lytic gene, PAN, which is
activated during KSHV lytic replication. Therefore, GFP serves as a marker for infected cells
while RFP serves as a marker for KSHV lytic replication. As shown in Fig 1A, while Dox suc-
cessfully induced KSHV reactivation and lytic replication in both non-specific (NS) siRNA
and NLRX1 siRNA transfected cells at each time point, there were lower percentages of RFP
positive cells in the NLRX1 depleted samples. Moreover, while we did not observe significant
GFP variation, RFP intensity quantitation showed significant inhibition of RFP intensity in
the NLRX1 siRNA transfected samples compared to the control NS siRNA transfected sam-
ples. This suggests that KSHV lytic replication is suppressed in NLRX1 depleted cells (Fig 1B
and 1C). We also tested a second NLRX1 siRNA (siNLRX1 #2) and examined its effect on viral
reactivation by investigating RFP fluorescence. The results with the second NLRX1 siRNA was
similar to the first siRNA (S2A and S2B Fig). We next monitored KSHV viral particles in the
supernatant as well as in infected iSLK.219 cells from each group harvested at 24, 48 and 72
hours post reactivation. Consistent with RFP expression levels, we detected significantly fewer
KSHV genomes in the NLRX1 siRNA transfected samples compared to control NS siRNA
transfected samples as determined by KSHV genome copy number (Fig 1D and 1E). NLRX1
knockdown efficiency was checked by qRT-PCR (Fig 2A).
NLRX1 is required for optimal KSHV gene transcription and expression
upon reactivation
To determine the impact of NLRX1 on viral genes, we examined KSHV lytic gene expression.
Knockdown efficiency of NLRX1 was monitored by qRT-PCR (Fig 2A, S2E Fig). NLRX1 defi-
cient cells showed a reduced ability to induce lytic gene transcription (such as ORF57, vIRF1
and K8.1) than the control NS siRNA transfected cells (Fig 2B and 2C; S2C and S2D Fig). Both
ORF45 and K8alpha lytic proteins were downregulated at 24, 48 and 72 hours post reactivation
in the NLRX1 siRNA group (Fig 2D). Knockdown efficiency of NLRX1 was also monitored by
immunoblot analysis (Fig 2D). To broadly profile KSHV viral gene expression during reactiva-
tion in control versus NLRX1 depleted samples, we also performed KSHV whole genome
transcriptional profiling. As seen in Fig 2E, Dox treatment successfully induced KSHV gene
expression, and depletion of NLRX1 led to a suppression and delay of viral genome transcrip-
tion at each time point that we tested, which correlates well with our qRT-PCR data (Fig 2E).
We also monitored viral gene transcription at later time points, and we observed a smaller dif-
ference between the siNS and siNLRX1 groups at later time points (S3A–S3C Fig).
Loss of NLRX1 results in increased type I interferon responses
We next probed for the mechanism by which NLRX1 depletion restricts KSHV lytic reactiva-
tion from latency. In order to rule out the possibility that siNLRX1 affects the induction of
RTA, we tested if siNLRX1 would affect RTA mRNA transcription induced by Dox. Because
RTA transcription in iSLK.219 cells can be both affected by Dox and KSHV reactivation, we
used iSLK.RTA cells without KSHV infection to test if siNLRX1 would affect Dox induced
RTA. As shown in S3D and S3E Fig, knockdown of NLRX1 did not attenuate RTA mRNA
transcription.
Since NLRX1 has been reported to negatively regulate type I interferon, we then investi-
gated if NLRX1 altered type I interferon responses upon KSHV reactivation. As seen in Fig
3A, loss of NLRX1 did result in stronger ifnb transcriptional activity. IFNβ is known to activate
NLRX1 facilitates KSHV reactivation
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Fig 1. NLRX1 is required for optimal KSHV reactivation in iSLK.219 cells. (A) iSLK.219 cells were transfected with NS or NLRX1 siRNA for
48 hours and then treated with Dox for various time points. A representative image of a field of cells expressing GFP and RFP are shown at 0,
24, 48 and 72 hours post-Dox treatment. (B-C) Whole well GFP/RFP intensities were monitored and quantitated by a Clariostar plate reader.
NLRX1 facilitates KSHV reactivation
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the JAK/STAT pathway to induce ISGs for effective antiviral responses against viruses. To
investigate this further, we next tested whether the upregulated ifnb transcription level in
NLRX1 deficient cells led to the activation of the JAK/STAT pathway. We performed microar-
ray analysis of genes in the JAK/STAT pathway using KSHV infected cells that were trans-
fected with either control or NLRX1 siRNAs at timepoints of 0 hour, 24 hours and 48 hours
post reactivation. We compared JAK/STAT responsive genes that were activated in cells trans-
fected with NLRX1 and NS siRNA at each time point. At 0, 24 and 48 hours, many JAK/STAT
pathway genes were induced at least 2 fold higher in NLRX1 depleted cells compared to NS
siRNA transfected cells, indicating a higher potential for JAK/STAT pathway upregulation
upon NLRX1 depletion (Fig 3B–3D). Moreover, as shown in Fig 3E and 3F, at 24 hours post
Dox treatment, 16 genes were upregulated by 2 fold in the NS siRNA control samples while 48
genes were upregulated at least 2 fold in the in NLRX1 siRNA transfected samples. At 48 hours
post Dox treatment, 20 genes were upregulated by more than 2 fold in the NS siRNA control
samples while 46 genes were upregulated at least 2 fold in the NLRX1 siRNA transfected sam-
ples (Fig 3G and 3H). In summary, NLRX1 deficient cells induce a much wider variety of JAK/
STAT pathway related genes at each time point tested in KSHV reactivated cells compared to
the control cells. Fig 3I and S1 Table depicts the overall gene expression of all 84 JAK/STAT
related genes tested. As shown, most genes exhibit a higher expression level in NLRX1 defi-
cient cells compared to control cells at each time point tested. We noticed that many JAK/
STAT related genes were upregulated in the absence of KSHV lytic reactivation. To eliminate
that this is not due to an off target effect of the NLRX1 siRNA, we also tested an alternative
NLRX1 siRNA (siNLRX1 #2) to monitor the activation of the JAK/STAT pathway before
KSHV was reactivated. As shown in S4A–S4D Fig, we have also observed many upregulated
genes. Specifically, of 57 upregulated genes in siNLRX1 #2 group, 54 of the genes were also
upregulated in siNLRX1 group, compared to the siNS group. We also transiently overex-
pressed NLRX1 in iSLK.219 cells to explore the role of NLRX1 in KSHV reactivation. Consis-
tent with the siRNA experiments, we detected attenuated levels of IFNβ mRNA and increased
levels of viral ORF57 mRNA (S1A and S1B Fig). NLRX1 mRNA levels were monitored by
qRT-PCR (S1C Fig).
NLRX1 negatively regulates MAVS-dependent type I interferon
responses
NLRX1 was identified as a negative regulator of MAVS. Therefore, in order to further detail
the mechanism by which NLRX1 facilitates KSHV reactivation, we looked at IFNβ regulation
by MAVS. MAVS has previously been shown to play a role in limiting KSHV reactivation.
Therefore, we hypothesized that NLRX1 blocks MAVS to attenuate type I interferon responses
in KSHV-infected cells, and thus facilitates KSHV reactivation. To prove this, we first tested
the integrity and functionality of the MAVS signaling pathway. As shown in Fig 4A, we trans-
fected poly I:C into KSHV infected iSLK.219 cells and successfully triggered MAVS dependent
IFNβ induction, which is indicative of a functional RLR pathway. Moreover, NLRX1 depletion
in these cells resulted in higher induction of IFNβ, suggesting NLRX1 blocks MAVS signaling
in KSHV-infected iSLK.219 cells without reactivation. NLRX1 knockdown efficiency was
monitored by qRT-PCR (Fig 4B). We also tested if poly I:C, an activator of the MAVS pathway,
could mimic the effect of NLRX1 knockdown to inhibit KSHV reactivation. As shown in
(D) KSHV genome copy numbers in the supernatants of reactivated iSLK.219 cells. (E) KSHV genome copy numbers in reactivated iSLK.219
cells. Data are presented as mean ± s.d. from at least three independent experiments. * indicates p<0.05. ** indicates p<0.01 by Student’s t-
test.
https://doi.org/10.1371/journal.ppat.1006350.g001
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Fig 2. Loss of NLRX1 attenuates global KSHV gene expression upon reactivation. iSLK.219 cells were transfected with NS or
NLRX1 siRNA for 48 hours and then treated with Dox for various time points. (A) qRT-PCR of NLRX1 in reactivated iSLK.219 cells. (B)
qRT-PCR of K8.1 in reactivated iSLK.219 cells. (C) qRT-PCR of ORF57 in reactivated iSLK.219 cells. (D) Cells were harvested at the
indicated time points for Western blot analysis of NLRX1, ORF45, and K8alpha. Actin was monitored as loading control. (E) iSLK.219
cells were treated as described in the text. RNA was extracted from duplicate samples and KSHV viral transcript levels were analyzed
using a KSHV real-time qPCR-based whole genome array. mRNA levels of viral genes were normalized to the mRNA levels of
NLRX1 facilitates KSHV reactivation
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S5A–S5F Fig, poly I:C induced IFNβ during reactivation, and this correlated with inhibition of
KSHV reactivation as determined by RFP fluorescence and viral lytic gene expression.
To further test if NLRX1 blocks MAVS signaling in KSHV-infected cells upon reactivation,
we used BX795, an inhibitor of TBK1, which acts directly downstream of MAVS. As shown in
Fig 4C, when we treated cells with NLRX1 siRNA and BX795, we observed significant inhibi-
tion of IFNβ compared to the NLRX1 siRNA and vehicle only treated group at 24 and 48
hours post reactivation. IFNβ levels in the NLRX1 siRNA and BX795 treated group were simi-
lar to that of the NS siRNA treated group. NLRX1 knockdown efficiency was monitored by
qRT-PCR (Fig 4D). To eliminate the possibility that NLRX1 directly acts as a negative regula-
tor of IRF3, we tested whether NLRX1 could modulate IFNβ promoter luciferase activation by
an IRF3 super activator (SA). As shown in S1D–S1F Fig, NLRX1 overexpression inhibited
dRIG-I- or MAVS- dependent activation of the IFNβ promoter, but the IRF3(SA) activated
IFNβ promoter activation was not affected. These data suggest that NLRX1 inhibits MAVS in
KSHV-infected cells and supports KSHV lytic replication.
TBK1 inhibition by BX795 partially rescues KSHV reactivation and gene
expression
We next investigated whether BX795 inhibition of the MAVS-TBK1 node would rescue the
effect of NLRX1 depletion on KSHV reactivation. As shown in Fig 5A, while NLRX1 depletion
resulted in less RFP positive cells than the control NS siRNA group, BX795 treatment partially
rescued the block of lytic replication. RFP intensity quantitation also showed significant inhi-
bition of RFP intensity in NLRX1 siRNA treated samples compared to the control group, and
a subsequent increase of RFP intensity when the NLRX1 siRNA group was treated with BX795
(Fig 5C). No significant variations were observed in GFP intensity among groups (Fig 5B). We
then monitored KSHV viral particles from the reactivated cells from each group harvested at
24, 48 hours and 72 hours post reactivation. We detected significantly fewer KSHV virions in
cells transfected with NLRX1 siRNA compared to control NS siRNA samples, and a partial res-
cue of KSHV viral genomes upon BX795 treatment (Fig 5D). Similar patterns were observed
when we monitored KSHV ORF57 gene transcription levels in reactivated iSLK.219 cells (Fig
5E). NLRX1 depletion led to a significant inhibition of ORF57 gene transcription, but this was
partially rescued by BX795 treatment (Fig 5E).
Knockdown of TBK1 by siRNA rescues KSHV reactivation and gene
expression
To further corroborate our experimental data obtained with BX795 treatment, we also utilized
TBK1 specific siRNA. As shown in Fig 6A, while NLRX1 depletion resulted in fewer RFP posi-
tive cells than the control NS siRNA sample, siNLRX1+siTBK1 treatment rescued the block
to KSHV lytic reactivation and replication. RFP intensity quantitation also showed significant
inhibition of RFP intensity in NLRX1 siRNA treated samples compared to the control samples
and a recovery of RFP intensity when the NLRX1 siRNA group was co-transfected with
siNLRX1 and siTBK1 (Fig 6C). No significant variations were observed in GFP intensity
among groups (Fig 6B). We also monitored multiple KSHV viral gene transcripts in reacti-
vated iSLK.219 cells. As shown in Fig 6D–6G, NLRX1 depletion led to significant inhibition of
multiple cellular housekeeping genes to yield dCT as a measure of relative expression. These were then subjected to unsupervised
clustering. A heat map and dendrogram depicted by the brackets is shown. Higher transcript expression levels are indicated by red
and lower expression levels by blue as shown in the key. Data are presented as mean ± s.d. from at least three independent
experiments. *indicates p<0.05. ** indicates p<0.01 by Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g002
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Fig 3. NLRX1 depletion results in enhanced interferon responses upon KSHV reactivation. iSLK.219 cells were transfected with NS or
NLRX1 siRNA for 48 hours and then treated with Dox for various time points. (A) IFNβmRNA levels were monitored by qRT-PCR. (B-D) RNA was
extracted from duplicate samples and various JAK/STAT related mRNA levels were analyzed using a JAK/STAT real-time qPCR-based gene array
NLRX1 facilitates KSHV reactivation
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ORF57, K8.1 and vIRF1 gene transcription, but they were all rescued when the cells were co-
transfected with TBK1 siRNA. NLRX1 knockdown efficiency was monitored by qRT-PCR as
shown in Fig 6D. We have also tested if TBK1 knockdown alone promoted KSHV replication
by examining viral lytic gene transcription by qRT-PCR. As shown in S6A–S6D Fig, TBK1
knockdown resulted in elevated transcription of viral genes, such as orf57, virf1 and k8.1.
NLRX1 is required for optimal KSHV reactivation and viral gene
expression in PEL
We also investigated NLRX1’s role in KSHV infected PEL cells. BCBL-1 is a KSHV-infected B
lymphoma cell line. We transfected NS or NLRX1 siRNA into BCBL-1 cells, and then induced
(details are listed in S1 Table). mRNA levels of genes were normalized to the mRNA levels of human β-actin to yield dCT as a measure or relative
expression without clustering. Scatter plot comparison of relative mRNA level at 0 (B), 24 (C) and 48 (D) hours between NLRX1 siRNA treated cells
and NS siRNA treated cells. (E-H) Scatter plot of relative mRNA level at 24 and 48 hours. NS siRNA group at 0 hours were set as normalization
control. (I) Heat map of the JAK/STAT microarray. Relative Z-scores of each gene level was calculated by subtracting mean values for each
individual gene, and then dividing by each gene standard deviation. Higher Z-scores are indicated by red, lower levels by blue as shown in the key.
Data are presented as mean ± s.d. from at least three independent experiments. *indicates p<0.05. ** indicates p<0.01 by Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g003
Fig 4. NLRX1 negatively regulates MAVS-dependent type I interferon response. (A) iSLK.219 cells were transfected with NS or
NLRX1 siRNA for 72 hours. Cells were then transfected with poly I:C at 2 μg/μl for 4 hours before being harvested. RNA was
subjected to IFNβ qRT-PCR analysis. (B) NLRX1 knockdown efficiency was monitored by qRT-PCR. (C) iSLK.219 cells were
transfected with NS, NLRX1 siRNA for 72 hours. 1 μM BX795 was then added to one set of NLRX1 siRNA transfected samples 6
hours before the cells were reactivated with Dox for 0, 24 and 48 hours. IFNβmRNA was monitored by qRT-PCR. (D) NLRX1
knockdown efficiency was monitored by qRT-PCR.
https://doi.org/10.1371/journal.ppat.1006350.g004
NLRX1 facilitates KSHV reactivation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006350 May 1, 2017 9 / 20
Fig 5. Block of TBK1 by BX795 partially rescues KSHV reactivation. iSLK.219 cells were transfected with NS, or NLRX1 siRNA for 72
hours. 1 μM BX795 was then added to one set of NLRX1 siRNA treated samples 6 hours before the cells were reactivated by Dox for 0, 24 and
48 hours. (A) A representative image of a field of cells expressing GFP and RFP are shown at 0, 24, and 48 hours post-Dox treatment. (B-C)
Whole well GFP/RFP intensities were monitored and quantitated by Clariostar plate reader. (D) KSHV genome copy number in reactivated
iSLK.219 cells. (E) qRT-PCR of ORF57 in reactivated iSLK.219 cells. Data are presented as mean ± s.d. from at least three independent
experiments. * indicates p<0.05. ** indicates p<0.01 by Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g005
NLRX1 facilitates KSHV reactivation
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Fig 6. TBK1 siRNA rescues KSHV reactivation. iSLK.219 cells were transfected with NS, NLRX1 siRNA or NLRX1+TBK1
siRNAs for 48 hours. iSLK.219 were then reactivated with Dox for 0, 24 and 48 hours. (A) A representative image of a field of
cells expressing GFP and RFP are shown at 0, 24, and 48 and hours post-Dox treatment. (B-C) Whole well GFP/RFP
intensities were monitored and quantitated by a Clariostar plate reader. (D) NLRX1 knockdown efficiency was monitored by
NLRX1 facilitates KSHV reactivation
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lytic replication of KSHV by addition of TPA and sodium butyrate (NaB) as previously
described [11]. The cells and supernatant were harvested at 0 hour, 24 hours and 48 hours post
reactivation, and KSHV genome copy number was determined by qRT-PCR. As shown in Fig
7A and 7B, NLRX1 depletion resulted in significant inhibition of KSHV viral replication both
in the cells and in the supernatant, as determined by the genome copy number. We also tested
KSHV gene transcription levels in reactivated BCBL-1 cells transfected with NLRX1 siRNA or
NS siRNA. NLRX1 depletion resulted in significant inhibition of lytic gene transcription such
as ORF57 (Immediate early), ORF36 (early), and K8.1 (late) than NS siRNA transfected cells
(Fig 7D–7F). NLRX1 knockdown efficiency was monitored by qRT-PCR as shown in Fig 7C.
Furthermore, we also introduced another siRNA (siNLRX1 #2) and performed qRT-PCR
assay to monitor the status of KSHV lytic genes in reactivated BCBL-1 cells. As shown in S7A–
S7D Fig, we observed that both NLRX1 siRNAs modulated KSHV reactivation similarly in
BCBL-1 cells.
Loss of NLRX1 results in enhanced type I interferon responses in BCBL-
1 cells
Because NLRX1 is a negative regulator of IFNβ, we tested if NLRX1 blocked type I interferon
responses upon KSHV reactivation. As seen in Fig 8A, NLRX1 depletion enhanced ifnb tran-
scriptional activity compared to the NS siRNA group, confirming NLRX1’s role in restricting
IFNβ. We then performed microarray analysis of the JAK/STAT pathway in BCBL-1 cells to
explore NLRX1’s effect on KSHV reactivation. We compared genes that were activated in cells
treated with NLRX1 siRNA or NS siRNA at 0, 24 and 48 hours post reactivation. At 0, 24 and
48 hours, a significant number of genes were induced at least 2 fold higher in NLRX1 siRNA
transfected cells compared to NS siRNA transfected cells, indicating a higher potential of JAK/
STAT pathway upregulation when NLRX1 is depleted in BCBL-1 cells (Fig 8B–8D). Moreover,
at 24 hours post reactivation, 21 genes were upregulated by more than 2 fold in the siNS group
while 41 genes in the siNLRX1 group were upregulated by 2 fold. At 48 hours post reactivation,
29 genes were upregulated by more than 2 fold in the siNS group while 49 genes in the
siNLRX1 group were upregulated by more than 2 fold. These data suggest that NLRX1 defi-
cient cells exhibited induction of a much wider variety of JAK/STAT pathway related genes at
each time point tested compared to the control groups (Fig 8E–8H). Fig 8I and S2 Table sum-
marizes the overall gene expression of all 84 JAK/STAT related genes tested. As shown, most
genes exhibit higher expression levels in NLRX1 depleted cells compared to control cells at
each time point tested.
Discussion
KSHV reactivation from latency is a complex process for both virus and host, which is tightly
regulated by a variety of signaling pathways. Efficient lytic replication of KSHV requires dis-
ruption of restrictive signaling pathways that keep the virus latent. This can be achieved by the
action of either viral proteins or host proteins. For example, upon KSHV reactivation, cytosolic
RNA and DNA dependent pathways were reported to be activated and type I interferon was
produced to suppress viral replication [8, 19]. Previously, we have reported that in order to
facilitate viral lytic replication, KSHV encodes multiple proteins to inhibit type I interferon
production, such as vIRF1. vIRF1 knockdown in the context of viral reactivation can result in
qRT-PCR. (E-G) qRT-PCR of ORF57, K8.1 and vIRF1 in reactivated iSLK.219 cells. Data are presented as mean ± s.d. from
at least three independent experiments. * indicates p<0.05. ** indicates p<0.01 by Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g006
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enhanced IFNβ production and insufficient reactivation [8]. While viral inhibitors of type I
interferon are important for KSHV lytic replication, in this study, we focused on exploring the
role of a host type I interferon inhibitor, NLRX1, during KSHV reactivation. We demonstrated
that NLRX1 is required for optimal KSHV reactivation. NLRX1 deficiency in iSLK.219 cells
Fig 7. NLRX1 is required for optimal KSHV reactivation in BCBL-1 cells. BCBL-1 cells were transfected with NS or NLRX1 siRNA for 48
hours and then treated with TPA and sodium butyrate for various time points. (A) KSHV genome copy number in reactivated BCBL-1 cells.
(B) KSHV genome copy number in the supernatants of reactivated BCBL-1 cells. (C) qRT-PCR of NLRX1 in reactivated BCBL-1 cells. (D)
qRT-PCR of ORF57 in reactivated BCBL-1 cells. (E) qRT-PCR of K8.1 in reactivated BCBL-1 cells. (F) qRT-PCR of ORF36 in reactivated
BCBL-1 cells. Data are presented as mean ± s.d. from at least three independent experiments. * indicates p<0.05. ** indicates p<0.01 by
Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g007
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Fig 8. NLRX1 knock down results in enhanced interferon responses upon KSHV reactivation in BCBL-1 cells. BCBL-1 cells were transfected
with NS or NLRX1 siRNA for 48 hours and then treated with TPA and sodium butyrate for various time points. (A) IFNβmRNA in BCBL-1 cells was
monitored by qRT-PCR. (B-D) RNA was extracted from duplicate samples and various JAK/STAT related mRNA levels were analyzed using a JAK/
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led to enhanced type I interferon production, as well as global suppression of KSHV genome
transcription activity, decreased level of lytic proteins, and attenuated virion production. A
similar phenotype was observed in BCBL-1 cells as well, suggesting NLRX1 is critical for
KSHV reactivation and subsequent replication in multiple cell lines. We noticed that viral
genes clustered together based on their expression patterns following NLRX1 depletion. A
future goal will be to further explore the differences among these different clusters to better
understand the regulation of KSHV reactivation.
NLRX1 was previously reported to suppress the RIG-I-MAVS signaling pathway, which is
triggered by cytosolic RNA [12]. It has also been previously reported that KSHV reactivation
generates dsRNA intermediates that can trigger RIG-I-MAVS signaling in KSHV-infected
cells [19]. As shown in our study, we demonstrate the functionality of the MAVS-dependent
pathway in both KSHV-infected iSLK.219 and BCBL-1 cells. More importantly, NLRX1 nega-
tively regulated MAVS-dependent IFNβ transcription before and after KSHV reactivation in
both iSLK.219 and BCBL-1 cells, indicating that NLRX1 regulates KSHV reactivation through
a MAVS-dependent pathway. Inhibition of type I interferon induction by the TBK1 antago-
nist, BX795, mitigated the effect of NLRX1 deficiency on KSHV lytic replication.
We have also explored TBK1’s effect on KSHV lytic reactivation. Although this is the first
time that TBK1 was reported to be a negative regulator of KSHV lytic reactivation, TBK1 was
previously reported as a restriction factor of RNA viruses, such as Newcastle Disease virus
(NDV) and Sendai virus (SeV), by acting downstream of MAVS and positively regulating IFN
responses [21, 22]. This correlates with our previously published results that MAVS play a neg-
ative role in KSHV reactivation [19]. Moreover, TBK1 also inhibits replication of HSV-1, an
alpha herpesvirus [23].
Although NLRX1 plays an important role in KSHV reactivation, we did not observe signifi-
cant upregulation or downregulation of NLRX1 at either the transcript or protein level during
KSHV reactivation. Therefore, it is possible that NLRX1 serves as a steady-state negative regu-
lator of type I interferon to facilitate KSHV reactivation. However, it is also plausible that
NLRX1 may undergo some type of post translational modifications upon KSHV reactivation,
which might further benefit KSHV lytic replication. A third possibility is that during lytic reac-
tivation, a KSHV encoded protein(s) might also bind directly or indirectly to the NLRX1 sig-
naling complex to regulate its function. In sum, we report for the first time that NLRX1 plays a
pivotal role in modulating KSHV reactivation from latency.
Materials and methods
Cell culture, reagents, and antibodies
iSLK.219 (doxycycline-inducible SLK cells harboring latent rKSHV.219) (a kind gift from
D. Ganem) were maintained in DMEM (Corning) supplemented with 10% FBS (Sigma), 1%
penicillin and streptomycin (Corning), G418 (250 μg/ml) (Sigma), hygromycin (400 μg/ml)
(Corning), and puromycin (10 μg/ml) (Corning). BCBL-1 cells (a kind gift from D. Ganem)
were maintained in RPMI (Corning) medium supplemented with 20% FBS, 1% penicillin and
streptomycin (Corning), 1% L-glutamine (Corning), and 0.05 mM β-mercaptoethanol
STAT real-time qPCR-based gene array. mRNA levels of viral genes were normalized to the mRNA levels of human β-actin to yield dCT as a measure
or relative expression without clustering. Scatter plot comparison of relative mRNA level at 0 (B), 24 (C) and 48 (D) hours between NLRX1 siRNA
treated cells and NS siRNA treated cells. (E-H) Scatter plot of relative mRNA level at 24 and 48 hours. NS siRNA group at 0 hours were set as the
normalization control. (I) Heat map of JAK/STAT microarray. Relative Z-scores of each gene level was calculated by subtracting mean values for each
individual gene, and then dividing by each gene standard deviation. Higher Z-scores are indicated by red, lower levels by blue as shown in the key.
Data are presented as mean ± s.d. from at least three independent experiments. *indicates p<0.05. ** indicates p<0.01 by Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006350.g008
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(Sigma). All cells were maintained at 37˚C in a 5% CO2 laboratory incubator subject to routine
cleaning and decontamination. poly(I:C) was purchased from Invivogen. Antibodies were
obtained from the following sources: mouse anti-NLRX1 (Jenny Ting laboratory), KSHV
ORF45 (MA5-14769) (Thermo Scientific), Goat anti β-actin-HRP (1615) (Santa Cruz), KSHV
K8.1alpha (SC-57889; Santa Cruz). The NLRX1 antibody was previously reported [12]. The
pCIG2-Puro and pCIG2-NLRX1-FLAG plasmids were previously described [17]. The dRIG-I
and MAVS expression plasmids were previously described [12]. pRL-CMV renilla vector was
obtained from Promega. IFNβ promoter luciferase was a generous gift from Zhijian Chen,
University of Texas Southwestern, Dallas. pUNO-IRF3sa was obtained from Invivogen.
siRNA transfections and reactivation of KSHV in iSLK.219 and BCBL-1
cells
iSLK.219 cells were maintained as described above and were transfected using Lipofectamine
RNAiMAX (Life Technologies) according to the manufacturer’s instructions. At 48 hours
post-transfection, the medium was changed to DMEM containing 1% Pen-Strep, 10% FBS,
and 0.2 μg/ml of doxycycline for reactivation [20]. BCBL-1 siRNA transfections were per-
formed using Lonza nucleofector V kit according to the manufacturer’s recommendations
(Lonza). BCBL-1 PEL cells were reactivated with 1 mM sodium butyrate (Sigma) and 25 ng/ml
12-O-tetradecanoyl-phorbol 13-acetate (TPA) (Sigma) where indicated. At 0, 24, 48 or 72
hours post-reactivation, cells and supernatant were collected. RNA was harvested from cells
via the RNeasy Plus mini kit (Qiagen) for analysis of levels of viral transcripts. DNA was har-
vested from both cells and supernatant via DNeasy mini kit (Qiagen) for analysis of genome
copy numbers. Protein from cells was harvested for WB analysis.
RNA interference
Chemically synthesized siRNA duplexes were obtained from Dharmacon GE. ON-TARGET-
plus Non-targeting Control siRNAs #1 (D-001810-01); ON-TARGETplus NLRX1 siRNA (J-
012926-10) Sequence: UCGUCAACCUGGUGCGCAA; ON-TARGETplus NLRX1 siRNA #2
(J-012926-12) Sequence: GUGCUGGGUUUGCGCAAGA; ON-TARGETplus TBK1 (29110)
siRNA SMARTpool (L-003788-00) Sequences: (J-003788-08) AGAAGGCACUCAUCCGAA
A; (J-003788-09) GAACGUAGAUUAGCUUAUA; (J-03788-10) UGACAGCUCAUAAGAU
UUA; (J-003788-11) GGAUAUCGACAGCAGAUUA
Quantitative Real-Time PCR
Total RNA was isolated by using RNeasy RNA extraction kit (Qiagen) and cDNA synthesis
was performed using iScript cDNA Synthesis Kit (Bio-rad) according to manufacture proto-
cols. Real-time PCR was performed using a ViiA 6 Real-Time PCR System. A SYBR green
assay from Bio-rad was used for human ifnb as well as KSHV ORFs detection. Primers used
for SYBR green qRT-PCR were:
KSHV orf57 F: 5’-TGGACATTATGAAGGGCATCCTA-3’; R: 5’-CGGGTTCGGACAATT
GCT-3’.
KSHV orf36 F: 5’-TGCGTCCTCTTCCAGTGTTA-3’; R: 5’-GTCAGCAGAGTGTAGCCC
AA-3’.
KSHV virf1 F: 5’-CGTGTCCTTTGGTGAAACTG-3’; R: 5’-TCGGCATTATTTCGAGTAC
G-3’.
KSHV k8.1 F: 5’-AAAGCGTCCAGGCCACCACAGA-3’; R: 5’-GGCAGAAAATGGCACA
CGGTTAC-3’.
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Human actin F: 5’-AAGACCTGTACGCCAACACA-3’; R: 5’-AGTACTTGCGCTCAGGA
GGA-3’.
Human ifnb F: 5’-AGTAGGGCGACACTGTTCGTG-3’; R: 5’-GAAGCACAACAGGAGA
GCAA-3’.
Human nlrx1 F: 5’-CCTCTGCTCTTCAACCTGATC-3’; R: 5’-CCTCTCGAAACATCTCC
AGC-3’.
Human tbk1 F: 5’- CCTCCCTAAAGTACATCCACG-3’; R: 5’- CAATCAGCCATCGTAT
CCCC-3’.
The relative amount of IFNβ, ORF57, ORF36 and K8.1 mRNA was normalized to actin
RNA level in each sample and the fold difference between the treated and mock samples was
calculated.
JAK-STAT array
Total RNA was isolated from iSLK.219 or BCBL-1 cells by using RNeasy RNA extraction kit
(Qiagen) and cDNA synthesis was performed using iScript™ cDNA Synthesis Kit (Bio-rad)
according to the manufacturer’s protocols. Human JAK/STAT Signaling Primer Library was
purchased from Realtimeprimers.com (Cat #: HJAK-I), which contains 88 primer sets directed
against human JAK/STAT related genes and 8 housekeeping gene primer sets. Fold-Change
(2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test Sample
divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample. Data were
analyzed by GENE-E software (https://software.broadinstitute.org/GENE-E/).
qPCR viral array
We used a real-time qPCR array to quantify all KSHV mRNAs. Briefly, 192 primer pairs were
included to target multiple regions towards the 3’ end of each annotated ORF. Multiple refer-
ence genes for cellular transcripts were included for normalization. The array results in ampli-
fication reactions with similar efficiencies and annealing temperatures and thus allows us to
directly compare the expression levels among different mRNAs. qPCR was plated in 384-well
plates using the Tecan Freedom Evo liquid handling robot and cycled using Roche LightCycler
480, as previously described. A detailed, step-by-step protocol is available at http://www.med.
unc.edu/vironomics/protocols.
Statistical analysis
Statistical significance of differences in cytokine levels, mRNA levels, viral titers, and luciferase
intensity in reporter assay were determined using Student’s t-test.  indicates P<0.05.  indi-
cates P<0.01.
Supporting information
S1 Fig. Overexpression of NLRX1 attenuates IFNβ and enhance KSHV gene expression
upon reactivation. iSLK.219 cells were transfected with vector or NLRX1 plasmids for 48
hours and then treated with Dox for various time points. (A) qRT-PCR of ifnb in reactivated
iSLK.219 cells. (B) qRT-PCR of orf57 in reactivated iSLK.219 cells. (C) qRT-PCR of nlrx1 in
reactivated iSLK.219 cells. (D-F) HEK293T cells were co-transfected as indicated with NLRX1
plasmid, IFNβ-luc (50ng) and pRL-CMV (10ng) with 50ng of dRIG-I (D), MAVS (E) or IRF3
(SA) (F). 48 hours later, luciferase activity were monitored.
(EPS)
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S2 Fig. Knockdown of NLRX1 attenuates KSHV gene expression upon reactivation.
iSLK.219 cells were transfected with NS, NLRX1 or NLRX1 #2 siRNA for 48 hours and then
treated with Dox for various time points. (A-B) Whole well GFP (A)/RFP (B) intensities were
monitored and quantitated by a Clariostar plate reader. (C-E) qRT-PCR of virf1 (C), k8.1 (D)
or nlrx1 (E) in reactivated iSLK.219 cells.
(EPS)
S3 Fig. Knockdown of NLRX1 attenuates KSHV gene expression upon reactivation with-
out affecting Dox-induced RTA expression. iSLK.219 cells were transfected with NS or
NLRX1 siRNA for 48 hours and then treated with Dox for various time points. (A-C)
qRT-PCR of nlrx1 (A), virf1 (B) or k8.1 (C) in reactivated iSLK.219 cells. iSLK.RTA cells were
transfected with NS or NLRX1 siRNA for 48 hours and then treated with Dox for 24h (D-E)
qRT-PCR of rta (D) or nlrx1 (E) in reactivated iSLK.RTA cells.
(EPS)
S4 Fig. Comparison of JAK/STAT related genes activated by knockdown of NLRX1 with-
out reactivation of KSHV in iSLK.219 cells. iSLK.219 cells were transfected with NS, NLRX1
or NLRX1 #2 siRNA for 48 hours. RNA was harvested from iSLK.219 and made into cDNA.
(A-B) Regulation of JAK/STAT related genes in siNLRX1 (A) or siNLRX1 #2 (B) were com-
pared to the siNS group. (C-D) Comparison of upregulated genes (C) or downregulated genes
(D) in two experiments.
(EPS)
S5 Fig. Poly I:C transfection activates IFNβ and inhibits KSHV gene expression upon reac-
tivation. iSLK.219 cells were transfected with NS or NLRX1 siRNA for 48 hours and then
treated with Dox for various time points. (A-B) Whole well GFP (A)/RFP (B) intensities were
quantitated by a Clariostar plate reader. (C-F) qRT-PCR of ifnb (C), orf57 (D), virf1 (E) or k8.1
(F) in reactivated iSLK.219 cells.
(EPS)
S6 Fig. Knockdown of TBK1 enhances KSHV gene expression upon reactivation. iSLK.219
cells were transfected with NS, or TBK1 siRNA for 48 hours and then treated with Dox for var-
ious time points. (A-D) qRT-PCR of tbk1 (A), orf57 (B), virf1 (C) or k8.1 (D) in reactivated
iSLK.219 cells.
(EPS)
S7 Fig. Knockdown of NLRX1 by a different NLRX1 siRNA enhances KSHV gene expres-
sion in reactivated BCBL-1 cells. BCBL-1 cells were transfected with NS or NLRX1 #2 siRNA
for 48 hours and then treated with Dox for various time points. (A-D) qRT-PCR of nlrx1 (A),
orf57 (B), virf1 (C) or k8.1 (D) in reactivated BCBL-1 cells.
(EPS)
S1 Table. iSLK.219 JAK/STAT pathway genes analysis in microarray.
(XLSX)
S2 Table. BCBL-1 JAK/STAT pathway genes analysis in microarray.
(XLSX)
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